Hematopoietic stem cells from induced pluripotent stem cells - considering the role of microRNA as a cell differentiation regulator

Autor(es)

Ferreira, Aline F. ^[1] ; Calin, George A. ^[2] ; Picanco-Castro, Virginia ^[3] ; Kashima, Simone ^[3] ; Covas, Dimas T. ^{[4, 3]} ; de Castro, Fabiola A. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Anal Toxicol & Food Sci, BR-14040903 Ribeirao Preto, SP - Brazil

^[2] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 - USA

^[3] Reg Blood Ctr Ribeirao Preto, Ctr Cell Therapy, BR-14051140 Ribeirao Preto, SP - Brazil

^[4] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, BR-14049900 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Journal of Cell Science; v. 131, n. 4 FEB 2018.
• Citações Web of Science: 6

Resumo

Although hematopoietic stem cell (HSC) therapy for hematological diseases can lead to a good outcome from the clinical point of view, the limited number of ideal donors, the comorbidity of patients and the increasing number of elderly patients may limit the application of this therapy. HSCs can be generated from induced pluripotent stem cells (iPSCs), which requires the understanding of the bone marrow and liver niches components and function in vivo. iPSCs have been extensively applied in several studies involving disease models, drug screening and cellular replacement therapies. However, the somatic reprogramming by transcription factors is a low-efficiency process. Moreover, the reprogramming process is also regulated by microRNAs (miRNAs), which modulate the expression of the transcription factors OCT-4 (also known as POU5F1), SOX-2, KLF-4 and MYC, leading somatic cells to a pluripotent state. In this Review, we present an overviewof the challenges of cell reprogramming protocols with regard to HSC generation from iPSCs, and highlight the potential role of miRNAs in cell reprogramming and in the differentiation of induced pluripotent stem cells. (AU)

• Processo FAPESP: 15/21237-4 - Determinação do perfil de metilação de células-tronco hematopoéticas pré-leucêmicas e leucêmicas de leucemia mielóide aguda pelo ensaio "single cell dna methylation"
• Beneficiário: Fabíola Attié de Castro
• Modalidade de apoio: Bolsas no Exterior - Pesquisa
• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs